Rhedin Samuel, Elfving Kristina, Berggren Anna
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, s-171 65 Stockholm, Sweden.
Sachs' Children and Youth Hospital, Södersjukhuset, s-118 61 Stockholm, Sweden.
Children (Basel). 2021 Nov 20;8(11):1070. doi: 10.3390/children8111070.
Differentiating viral from bacterial infections in febrile children is challenging and often leads to an unnecessary use of antibiotics. There is a great need for more accurate diagnostic tools. New molecular methods have improved the particular diagnostics of viral respiratory tract infections, but defining etiology can still be challenging, as certain viruses are frequently detected in asymptomatic children. For the detection of bacterial infections, time consuming cultures with limited sensitivity are still the gold standard. As a response to infection, the immune system elicits a cascade of events, which aims to eliminate the invading pathogen. Recent studies have focused on these host-pathogen interactions to identify pathogen-specific biomarkers (gene expression profiles), or "pathogen signatures", as potential future diagnostic tools. Other studies have assessed combinations of traditional bacterial and viral biomarkers (C-reactive protein, interleukins, myxovirus resistance protein A, procalcitonin, tumor necrosis factor-related apoptosis-inducing ligand) to establish etiology. In this review we discuss the performance of such novel diagnostics and their potential role in clinical praxis. In conclusion, there are several promising novel biomarkers in the pipeline, but well-designed randomized controlled trials are needed to evaluate the safety of using these novel biomarkers to guide clinical decisions.
区分发热儿童的病毒感染和细菌感染具有挑战性,且常常导致抗生素的不必要使用。非常需要更准确的诊断工具。新的分子方法改进了病毒呼吸道感染的特异性诊断,但确定病因仍可能具有挑战性,因为在无症状儿童中经常检测到某些病毒。对于细菌感染的检测,灵敏度有限且耗时的培养方法仍然是金标准。作为对感染的反应,免疫系统引发一系列事件,旨在消除入侵的病原体。最近的研究集中在这些宿主-病原体相互作用上,以识别病原体特异性生物标志物(基因表达谱)或“病原体特征”,作为未来潜在的诊断工具。其他研究评估了传统细菌和病毒生物标志物(C反应蛋白、白细胞介素、黏液病毒抗性蛋白A、降钙素原、肿瘤坏死因子相关凋亡诱导配体)的组合以确定病因。在本综述中,我们讨论了此类新型诊断方法的性能及其在临床实践中的潜在作用。总之,有几种有前景的新型生物标志物正在研发中,但需要精心设计的随机对照试验来评估使用这些新型生物标志物指导临床决策的安全性。